Musab S. Hommos

Musab S. Hommos

Auto-generated profile, based on publicly available information

Musab S. Hommos

Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ (M.S.H.).

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
MHMusab S. Hommos
Musab S. Hommos
RGRichard J. Glassock
Richard J. Glassock
ARAndrew D. Rule
Andrew D. Rule
Aging is associated with significant changes in structure and function of the kidney, even in the absence of age-related comorbidities. On the macrostructural level, kidney cortical volume decreases, surface roughness increases, and the number and size of simple renal cysts increase with age. On the microstructural level, the histologic signs of nephrosclerosis (arteriosclerosis/arteriolosclerosis, global glomerulosclerosis, interstitial fibrosis, and tubular atrophy) all increase with age. The decline of nephron number is accompanied by a comparable reduction in measured whole-kidney GFR. However, single-nephron GFR remains relatively constant with healthy aging as does glomerular volume. Only when glomerulosclerosis and arteriosclerosis exceed that expected for age is there an increase in single-nephron GFR. In the absence of albuminuria, age-related reduction in GFR with the corresponding increase in CKD (defined by an eGFR<60 ml/min per 1.73 m2) has been shown to associate with a very modest to no increase in age-standardized mortality risk or ESRD. These findings raise the question of whether disease labeling of an age-related decline in GFR is appropriate. These findings also emphasize the need for a different management approach for many elderly individuals considered to have CKD by current criteria.

1 December 2017 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MHMusab S. Hommos
Musab S. Hommos
AVAn S. De Vriese
An S. De Vriese
MAMariam P. Alexander
Mariam P. Alexander
SSSanjeev Sethi
Sanjeev Sethi
LVLisa Vaughan
Lisa Vaughan
FFFernando C. Fervenza
Fernando C. Fervenza

1 May 2018 in Kidney International
Verified
Journal Article
Closed access
MHMusab S. Hommos
Musab S. Hommos
CZCaihong Zeng
Caihong Zeng
ZLZhihong Liu
Zhihong Liu
JTJonathan P. Troost
Jonathan P. Troost
ARAvi Z. Rosenberg
Avi Z. Rosenberg
ARAndrew D. Rule
Andrew D. Rule

26 June 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MPMargaret M Paul
Margaret M Paul
NKNandita Khera
Nandita Khera
PEPraneetha R Elugunti
Praneetha R Elugunti
KRKevin C Ruff
Kevin C Ruff
MHMusab S Hommos
Musab S Hommos
MKManreet Kaur
Manreet Kaur
Remote patient monitoring (RPM) increased exponentially during the COVID-19 pandemic. RPM programs commonly incorporate tools to capture and transmit health-relevant data from the home to the clinical space to augment the clinical decision-making process of health care providers. Given the potential to improve patient health outcomes, health care systems around the world are actively engaged in fashioning, implementing, and exploring the outcomes of various RPM program models. However, new challenges to health care systems include increasing RPM program enrollment, optimizing condition-specific RPM programs to best address the needs of specific patient groups, integrating new RPM-derived data streams into existing IT infrastructure, overcoming limited availability of desired remote monitoring technologies, and quantifying the health outcomes produced by RPM use. Herein, we identify stakeholders for RPM in the United States, summarize the landscape of RPM tools available for chronic disease management, discuss the current regulatory environment, delve into the benefits and challenges of integrating these tools into clinical practice, summarize aspects of coverage and reimbursement, and examine the knowledge and policy gaps regarding sustained use of RPM in clinical practice, along with associated opportunities.

1 March 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
SSSami Safadi
Sami Safadi
MHMusab S. Hommos
Musab S. Hommos
FEFelicity T. Enders
Felicity T. Enders
JLJohn C. Lieske
John C. Lieske
Kianoush KashaniKianoush Kashani
Kianoush Kashani

1 August 2017 in Transplantation Direct
Verified
Journal Article
Open access
PDF file
MHMusab S. Hommos
Musab S. Hommos
ZEZiad M. El-Zoghby
Ziad M. El-Zoghby
Background: End-stage liver disease (ESLD) is the most common cause of secondary immunoglobulin A nephropathy (IgAN). Multiple mechanisms have been proposed to explain the association between liver disease and IgAN. Although some mechanisms are expected to reverse in patients after liver transplant, the long-term renal prognosis is unclear for these patients. Methods: This observational retrospective cohort study examined the renal outcomes of 14 patients who had IgAN with end-stage liver disease and subsequently underwent either liver transplant alone or combined liver and kidney transplant at a single tertiary care center. Results: Of the 7 patients who underwent liver transplant alone, hematuria persisted in 2, 4 had progressive loss of kidney function with worsening proteinuria in 3 but only 1 reached end-stage renal disease 5 years posttransplant. Among 7 combined liver and kidney transplant recipients, 1 had histologic and 1 had histologic and clinical recurrence of IgAN without kidney allograft loss. Conclusions: IgAN in patients with advanced liver disease does not necessarily resolve after liver transplant but has overall favorable renal outcomes.